agilon health, inc. (NYSE:AGL) Sees Significant Growth in Short Interest

agilon health, inc. (NYSE:AGL) saw a large increase in short interest in the month of November. As of November 30th, there was short interest totalling 31,940,000 shares, an increase of 5.1% from the November 15th total of 30,390,000 shares. Based on an average daily volume of 4,590,000 shares, the days-to-cover ratio is presently 7.0 days. Currently, 10.5% of the company’s shares are sold short.

agilon health Stock Down 8.4 %

agilon health stock traded down $0.19 during midday trading on Tuesday, hitting $2.01. The stock had a trading volume of 3,411,171 shares, compared to its average volume of 4,855,191. The company has a current ratio of 1.29, a quick ratio of 1.29 and a debt-to-equity ratio of 0.06. The stock has a market cap of $826.10 million, a P/E ratio of -2.13 and a beta of 0.51. agilon health has a 12 month low of $1.50 and a 12 month high of $13.45. The business has a fifty day moving average price of $2.40 and a 200 day moving average price of $4.32.

agilon health (NYSE:AGL) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.19). The firm had revenue of $1.45 billion during the quarter, compared to the consensus estimate of $1.47 billion. agilon health had a negative net margin of 6.88% and a negative return on equity of 47.84%. During the same period in the prior year, the firm earned ($0.06) earnings per share. Research analysts predict that agilon health will post -0.52 EPS for the current year.

Insiders Place Their Bets

In other agilon health news, Director Diana Mckenzie purchased 12,500 shares of agilon health stock in a transaction on Monday, November 25th. The shares were bought at an average price of $2.28 per share, with a total value of $28,500.00. Following the purchase, the director now directly owns 51,319 shares in the company, valued at $117,007.32. This trade represents a 32.20 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director John William Wulf bought 45,000 shares of the business’s stock in a transaction that occurred on Thursday, December 5th. The stock was purchased at an average cost of $2.18 per share, for a total transaction of $98,100.00. Following the completion of the transaction, the director now directly owns 206,133 shares in the company, valued at approximately $449,369.94. This trade represents a 27.93 % increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 90,000 shares of company stock valued at $198,100 in the last quarter. 3.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On agilon health

A number of hedge funds and other institutional investors have recently bought and sold shares of AGL. CWM LLC boosted its stake in agilon health by 406.5% in the second quarter. CWM LLC now owns 9,081 shares of the company’s stock valued at $59,000 after acquiring an additional 7,288 shares during the period. Nisa Investment Advisors LLC acquired a new position in shares of agilon health during the second quarter worth approximately $60,000. Neo Ivy Capital Management acquired a new position in shares of agilon health during the second quarter worth approximately $1,006,000. Pallas Capital Advisors LLC acquired a new position in shares of agilon health during the second quarter worth approximately $77,000. Finally, Bank of New York Mellon Corp boosted its position in shares of agilon health by 18.7% during the second quarter. Bank of New York Mellon Corp now owns 1,108,921 shares of the company’s stock worth $7,252,000 after buying an additional 174,883 shares during the period.

Wall Street Analyst Weigh In

AGL has been the topic of a number of research analyst reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $3.00 target price on shares of agilon health in a report on Tuesday, November 19th. Stifel Nicolaus reduced their target price on agilon health from $7.00 to $2.00 and set a “hold” rating on the stock in a report on Tuesday, November 12th. Macquarie began coverage on agilon health in a report on Monday. They issued a “neutral” rating and a $3.00 target price on the stock. Citigroup cut their price objective on agilon health from $2.50 to $1.75 and set a “sell” rating on the stock in a research report on Wednesday, November 13th. Finally, Sanford C. Bernstein began coverage on agilon health in a research report on Wednesday, December 11th. They issued a “market perform” rating and a $2.50 price objective on the stock. Three investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $4.28.

agilon health Company Profile

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.